← Back to all trials
Completed
NCT06086899
The Efficacy and Safety of Early MSAT on Radiating Pain in the Upper Extremity
Conditions: Radiating Pain in the Upper Extremity
Sex: All
Ages: 19 Years – 69 Years
Healthy volunteers: No
Phase: NA
Enrollment: 100
Sponsor: Jaseng Medical Foundation
Location: Jaseng Hospital of Korean Medicine Seoul Gangnam-Gu
Summary
This study is a open-label, randomized controlled trail. condition/disease: radiating pain in the upper extremity. treatment/intervention: motion style acupuncture treatment
Eligibility Criteria
Inclusion Criteria:
* Patients aged 19-69 years on the date they sign the consent form.
* Patients who are suffered byradiating pain in the upper extremity that occurred within 3 days after traffic accident.
* Patients who are hospitalized due to traffic accident.
* Patients with NRS of radiating pain ≥ 5.
* Patients who provide consent to participate in the trial and return the informed consent form.
Exclusion Criteria:
* Patients with a specific serious disease that may cause radiating pain: malignancy, spondylitis, inflammatory spondylitis, etc.
* Patients with progressive neurological deficits or with severe neurological symptoms.
* Patients with medical history of cervical surgery or thoracic surgery within the last three weeks.
* Patients who have radiating pain in upper extremity before the traffic accident.
* Patients with a specific serious disease that may interfere with the interpretation of the therapeutic effects or results: malignancy, spondylitis, inflammatory spondylitis, etc.
* Patients who are taking steroids, immunosuppressants, mental illness drugs, or other drugs that may affect the results of the study.
* If acupuncture is inadequate or unsafe: patients with hemorrhagic, receiving anticoagulants, severe diabetes and cardiovascular disease.
* Patients who are pregnant or planning to become pregnant.
* Patients who are participated in clinical trials other than observational studies without therapeutic intervention.
* Patients who are difficult to complete the research participation agreement.
* Other patients whose participation in the trial is judged by a researcher to be problematic.
Source: ClinicalTrials.gov (NCT06086899). StuddyBuddy aggregates publicly available trial information.